A Phase 3 Open-label Study to Evaluate the Safety of MEDI3250 in Healthy Japanese Children Age 2 Years Through 6 Years
Phase of Trial: Phase III
Latest Information Update: 01 Oct 2015
At a glance
- Drugs MEDI 3250 (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Registrational
- Sponsors AstraZeneca
- 02 Sep 2015 According to a Daiichi Sankyo media release, data from this will support regulatory submission in Japan.
- 09 Mar 2015 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 22 Dec 2014 Planned End Date changed from 1 May 2015 to 1 Mar 2015, according to ClinicalTrials.gov record.